Drug Injury Lawyer Blog

Stryker has issued a voluntary recall on its Rejuvenate Modular Hip. While the Stryker Rejuvenate can be used as a component of either metal or ceramic hip implants, the metal on metal modular component can potentially cause fretting and corrosion that may result in pain, swelling, tissue damage and metallosis. The Rejuvenate System can also lead to premature failure due to aseptic loosening and possibly pseudotumor formation.

Continue reading " Stryker Rejuvenate Hip Recall " »

The Biomet Magnum hip replacement device is a metal on metal system which includes chromium and cobalt in its composition. The friction caused by the metal components rubbing against one another can result is metal fragment being released into the surrounding tissue and blood stream. These metal fragments can lead to tissue damage including inflammation, bone loss, necrosis, and blood poisoning known as metallosis. Other possible side effects from hip implants include loosening, dislocation and possible fracture.

Continue reading " Biomet Magnum Metal on Metal Hips Can Result in Premature Failure As Well as Chromium-Cobalt Poisoning " »

Israeli newspaper Ha'aretz (7/2, Ben) reported that, "The highest-ever award in an Israeli class-action suit against a drug manufacturer – NIS 12.1 million – was recently made under a compromise agreement reached between a diabetes patient and GlaxoSmithKline, the maker of Avandia. The suit had been filed by a diabetic who claimed that GSK had concealed data from the public that showed the drug, which is used to treat people with type-2 diabetes, increased the risk of dying from a heart attack."

In continuing coverage, the AP (7/6) reports from Boston, "A federal judge on Thursday approved an agreement by British drugmaker GlaxoSmithKline to pay $3 billion for criminal and civil violations involving 10 drugs, the largest health care fraud settlement in US history." The AP adds, "The amount of money involved led US District Judge Rya Zobel to remark in court that she was having trouble keeping track of the numbers. GlaxoSmithKline pleaded guilty to promoting the popular antidepressants Paxil and Wellbutrin for unapproved uses."

Continue reading " Judge approves GlaxoSmithKline's $3 billion settlement with DOJ. " »